Contact CVRx Contact CVRx

BeAT–HF trial

Sustained symptomatic improvements

Barostim plus GDMT provides significant and meaningful improvements for heart failure patients beyond GDMT alone

+44 Meters at
12 months

Exercise capacity
(6MHW)1

exercise capacity(6mhw) chart from the beat-hf trial
-10 Points at 24 months

Quality of life
(MLWHF)1

quality of life (mlwhf) chart from the beat-hf trial
27% More patients improved at 24 months

Functional status
(NYHA class)1

functional status (nyha class) chart from the beat-hf trial

Freedom from all-cause death,
LVAD, and transplant1

34% Relative Reduction

HR 0.662 (95% CI 0.435, 1.007)

Patients in the Barostim arm had a 34% reduction in all-cause death or the use of LVAD or heart transplant at > 4 years follow-up

freedom from all-cause death, LVAD, and transplant chart from the beat-hf trial

Hierarchical composite using
win ratio analysis1

1.26

HR 1.26 (95% CI 1.02, 1.58)

26% more patients in the Barostim arm had better outcomes as evaluated by hierarchical composite of CV mortality, LVAD/transplant, HF hospitalization and quality of life

Safe procedure1

97%

Freedom from major adverse neurological or cardiovascular system or procedure-related event rate in the Barostim arm

Physician brochure thumbnail

Physician brochure

View / Download
CME thumbnail

CME

Access Course
full beat-hf trial summary thumbnail

Full clinical trial summary

View / Download
More Publications

1. Instructions for Use 900133-001 Rev. D available at www.cvrx.com/ifu; 2. Gremeaux V, et al. Arch Phys Med Rehabil. 2011;92(4):611-619.; 3. Rector TS, et al. J Card Fail. 1995;1(3):201-216;

Ready to learn more about Barostim?